[{"indications": "Indications\u00a0see under Dose", "name": "SODIUM CLODRONATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.6 Drugs affecting bone metabolism", "6.6.2 Bisphosphonates and other drugs affecting bone metabolism", "Bisphosphonates", "SODIUM CLODRONATE"], "cautions": "Cautions\u00a0monitor renal and hepatic function and white cell\r\ncount; also monitor serum calcium and phosphate periodically; renal dysfunction reported in patients receiving concomitant NSAIDs; maintain adequate fluid intake during treatment; consider dental check-up before initiating bisphosphonate (risk of osteonecrosis of the jaw, see Bisphosphonates: Osteonecrosis\r\nof the Jaw); atypical femoral fractures, see MHRA/CHM advice; interactions: Appendix 1 (bisphosphonates)", "side-effects": "Side-effects\u00a0nausea, diarrhoea, skin reactions, bronchospasm; rarely atypical femoral fractures (see MHRA/CHM advice); very rarely osteonecrosis of the jaw (see Bisphosphonates: Osteonecrosis\r\nof the Jaw)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4456.htm", "doses": ["Osteolytic lesions, hypercalcaemia and bone pain associated\r\nwith skeletal metastases in patients with breast cancer or multiple\r\nmyeloma, by mouth, 1.6\u00a0g daily in single or 2 divided\r\ndoses increased if necessary to a max. of 3.2\u00a0g daily", "Avoid food for 1 hour before and after\r\ntreatment, particularly calcium-containing products e.g. milk; also\r\navoid iron and mineral supplements and antacids; maintain adequate\r\nfluid intake", "2 tablets daily in single or two divided doses; may be\r\nincreased to max. 4 tablets daily"], "pregnancy": "Pregnancy\u00a0avoid"}]